Dermavant Sciences Inc.
About Dermavant Sciences Inc.
Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company committed to fostering unprecedented change and unparalleled impact in immuno-dermatology. We’re doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways—all with one goal: transforming the lives of millions of patients with skin diseases.
74 articles with Dermavant Sciences Inc.
-
Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
3/15/2023
Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old.
-
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
3/15/2023
Dermavant Sciences today announced positive results from ADORING 2, one of two double-blind, randomized, vehicle-controlled Phase 3 studies to evaluate the efficacy and safety of topical VTAMA® (tapinarof) cream, 1% in pediatric subjects down to 2 years old and adult subjects with atopic dermatitis (AD).
-
Dermavant to Present Data from Multiple Studies of VTAMA® (tapinarof) cream, 1% at the 2023 American Academy of Dermatology Annual Meeting
3/10/2023
Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that data from multiple studies of VTAMA® (tapinarof) cream, 1% will be presented at the 2023 American Academy of Dermatology Annual Meeting, to be held from March 17-21 in New Orleans, Louisiana.
-
Dermavant Completes Enrollment of Two Phase 3 Clinical Trials of VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children as Young as 2 years old
2/13/2023
Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that it has completed patient enrollment in its ADORING 1 and 2 Phase 3 clinical trials of VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children as young as 2 years old.
-
Dermavant to Present Data from Multiple Studies of VTAMA® (tapinarof) cream, 1% at the 2023 Winter Clinical Dermatology Conference
1/12/2023
Dermavant to Present Data from Multiple Studies of VTAMA ® (tapinarof) cream, 1% at the 2023 Winter Clinical Dermatology Conference.
-
Dermavant Launches First Commercial for VTAMA® (tapinarof) cream, 1% as Part of a National, Multimedia Campaign for Adults with Plaque Psoriasis
11/22/2022
Dermavant Launches First Commercial for VTAMA ® (tapinarof) cream, 1% as Part of a National, Multimedia Campaign for Adults with Plaque Psoriasis.
-
Dermavant Announces Highly Favorable Results from Pediatric Maximal Usage Study of VTAMA® (tapinarof) cream, 1% in Atopic Dermatitis
11/8/2022
Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced positive results from its maximal usage study of VTAMA® (tapinarof) cream, 1% in children down to age 2 years old with extensive burden of atopic dermatitis.
-
Dermavant to Present Data from Multiple Clinical Trials of VTAMA® (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference
10/13/2022
Dermavant to Present Data from Multiple Clinical Trials of VTAMA ® (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference.
-
Fortune and Great Place to Work® Name Dermavant One of the Best Small Workplaces™ and Best Workplaces in Biopharma™ in 2022
9/7/2022
Dermavant Sciences announced the company has been named one of the 2022 Best Small Workplaces™ and 2022 Best Workplaces in Biopharma™ by Fortune magazine and Great Place to Work® — Dermavant’s fourth and fifth recognitions by the organizations.
-
Dermavant to Present New Data from Phase 3 Trial Program of VTAMA® (tapinarof) cream, 1% for Adults with Plaque Psoriasis at the 2022 EADV Congress
8/24/2022
Dermavant Sciences today announced it will present data from its Phase 3 PSOARING trial program of VTAMA® (tapinarof) cream, 1% at the 31st European Academy of Dermatology and Venereology (EADV) Congress, to be held September 7-10 in Milan, Italy.
-
VTAMA® (tapinarof) Cream, 1% PSOARING 3 Final Data Published in JAAD
6/28/2022
Dermavant Sciences, today announced that new data from the one-year safety and efficacy final analyses of the Phase 3 PSOARING 3 long-term, open-label extension (“LTE”) study of VTAMA® (tapinarof) Cream, 1% for the treatment of plaque psoriasis in adults was published in the Journal of the American Academy of Dermatology (JAAD) on June 26, 2022.
-
FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years
5/24/2022
Dermavant Sciences announced that the U.S. Food and Drug Administration has approved VTAMA® cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults.
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting
3/25/2022
Dermavant Sciences announced Phase 3 PSOARING 3 long-term extension study results demonstrating durable improvements across efficacy outcomes, quality of life measures, and tolerability scores with investigational tapinarof cream 1% once daily for the treatment of plaque psoriasis in adults.
-
Dermavant to Present New Data from the Phase 3 PSOARING 3 Long-Term Extension Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 American Academy of Dermatology Annual Meeting
3/11/2022
Dermavant Sciences today announced that new data from the Phase 3 PSOARING 3 long-term extension study of tapinar cream.
-
BioSpace Movers & Shakers, March 11
3/11/2022
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers -
Dermavant Appoints Nancy Beesley to its Board of Directors
3/8/2022
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, announced the appointment of Nancy Beesley to its Board of Directors.
-
Clinical Catch-Up: January 17-21
1/24/2022
Last week was a relatively quiet week for clinical trial news, particularly around COVID-19. Here’s a look. -
Dermavant Presents New Patient Satisfaction Data from PSOARING 3 Long Term Extension Trial of Tapinarof in Adults with Plaque Psoriasis at the 2022 Winter Clinical Dermatology Conference
1/15/2022
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, announced results from a patient satisfaction questionnaire in the long-term, open-label Phase 3 PSOARING 3 extension study of tapinarof cream 1% once daily for the treatment of plaque psoriasis in adults.
-
Dermavant to Present New Data from Phase 3 PSOARING Program at the 2022 Winter Clinical Dermatology Conference
1/7/2022
Dermavant Sciences today announced that new patient satisfaction data from PSOARING 3, the long-term extension study of tapinarof cream for the treatment of plaque psoriasis in adults, will be presented at the 2022 Winter Clinical Dermatology Conference, to be held Jan. 14-19 in Koloa, Hawaii.